Andres Acosta

We've spent years using GLP-1 therapies. But what if some patients actually have GLP-1 deficiency?
Our new study identifies a distinct obesity subtype with reduced GLP-1 synthesis and enhanced response to tirzepatide—supporting precision medicine
authors.elsevier.com/a/1nRy83mEmrGQq

Day #4 at #DDW2026

We have an impressive line-up of abstracts.
- Tirzepatide Super-responder SubPhenotype
- LLM for obesity and semaglutide
- ML-GRS for CTS for Bariatric surgery
- ML-GRS for CTS for Phentermine-Topiramate
- LLM for obesity journey

Come to see them!

Excited to be at #OM2026 @OMAsocial Obesity Medicine Association annual meeting to learn, meet old friends, make new friends and off course, talk about phenotyping and genetics for best #GLP1 and other OM responders. #obesity #precisionobesity - @MayoClinic @phenomixscienc1

Excited to arrive at #IFSO2025 ⁦@IfsoSecretariat⁩ to present about #PrecisionObesity and #PrecisionBariatric: the next Frontier together with ⁦@rvcohen⁩. Join us at our early tomorrow morning symposium in beautiful Santiago, Chile. ⁦@MayoClinic⁩

Thank you @ScienceNews for featuring our work! Honored! @MayoClinicGIHep @MayoClinic